Source: https://brinksgilson.com/biographies/jason-schigelone
Timestamp: 2019-04-22 14:58:54+00:00

Document:
Jason was elected as counsel for Brinks Gilson & Lione effective in January 2015.
Jason has successfully litigated on numerous occasions on behalf of long-time client Cook Incorporated. This includes a recent victory in the U.S. District Court for the Southern District of Indiana involving Cook’s Zenith® endovascular grafts used in treating abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs). Jason is defending Cook against infringement claims brought by Endotach LLC. The district court granted summary judgment in Cook Medical’s favor, resulting in the dismissal of the case. Endotach appealed to the Federal Circuit of Appeals. The appeal is currently pending.
With a decade worth of experience in the automotive industry, Jason brings a strong engineering background, and a unique, real-world perspective to his clients and caseload.
LifePort Sciences LLC and LifeScreen Sciences LLC v. Cook Incorporated and Cook Medical Incorporated (D. Del. 2013-present). Mr. Schigelone represents Cook Incorporated and Cook Medical in several patent infringement actions filed by LifePort and LifeScreen concerning endovascular stent graft and vena cava filter technologies.
Endotach LLC v. Cook Medical Inc. (S.D. Ind. 2012-present). Mr. Schigelone represents Cook Medical in a patent infringement action filed by Endotach concerning endovascular stent grafts for treating aneurysms.
Boston Scientific Corp., Boston Scientific Scimed, Inc., Boston Scientific Ltd., and Endovascular Technologies, Inc. v. Cook Incorporated, Wilson-Cook Medical, Inc., Cook Medical Inc., Cook Ireland Ltd., Taewoong Medical Co., Ltd., Standard Sci-Tech Inc., EndoChoice, Inc., and Sewoon Medical Co., Ltd. (D. Mass. 2010). Mr. Schigelone represents the Cook entities in a patent infringement action concerning stents for treating blockages, such as cancer, in the esophagus.
Cook Incorporated v. Endologix, Inc. (S.D. Ind. 2009). Mr. Schigelone represented Cook Incorporated in a patent infringement action concerning endovascular stent grafts for treating abdominal aortic aneurysms.
AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals, Inc., Astrazeneca AB, and The Brigham and Women’s Hospital, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2010). Mr. Schigelone represented Teva Pharmaceuticals USA in a second Hatch-Waxman action concerning the cholesterol-lowering drug, Crestor®, and its active ingredient, rosuvastatin calcium.
Millennium Pharmaceuticals, Inc. and Schering Corp. v. Teva Parenteral Medicines, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries Ltd. (D. Del. 2009). Mr. Schigelone represented Teva Parenteral Medicines, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries in a Hatch-Waxman patent infringement action concerning the anti-coagulant drug, Integrilin®, and its active ingredient, eptifibatide.
AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, IPR Pharmaceuticals Inc., and Shionogi Seiyaku Kabushiki Kaisha v. Teva Pharmaceuticals USA, Inc. (D. Del. 2008-present). Mr. Schigelone represents Teva Pharmaceuticals USA in a Hatch-Waxman action concerning the cholesterol-lowering drug, Crestor®, and its active ingredient, rosuvastatin calcium.
Edwards Lifesciences, LLC and EndoGAD Pty, Ltd. v. Cook Incorporated, Medtronic, Inc., Medtronic AVE, Inc., and W.L. Gore & Associates, Inc. (N.D. California 2003-2009). Mr. Schigelone represented Cook Incorporated in a patent infringement action concerning endovascular stent-grafts for treating aneurysms.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.